Provided by Tiger Trade Technology Pte. Ltd.

Health Care Select Sector SPDR Fund

168.16
-0.6500-0.39%
Pre-market: 168.170.0100+0.01%04:01 EDT
Volume:11.12M
Turnover:1.86B
Market Cap:43.39B
PE:-11.83
High:168.51
Open:168.23
Low:165.19
Close:168.81
52wk High:176.60
52wk Low:141.05
Shares:258.02M
Float Shares:258.02M
Volume Ratio:1.37
T/O Rate:4.31%
Dividend:2.45
Dividend Rate:1.45%
EPS(TTM):-14.2170
EPS(LYR):-14.2170
ROE:-9.22%
ROA:1.03%
PB:1.26
PE(LYR):-11.83

Loading ...

Vital Healthcare Sets 2026 AGM to Ratify Manager and Board Reappointments

TIPRANKS
·
Oct 05

Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX) and Integra Lifesciences (IART)

TIPRANKS
·
Oct 03

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Oct 03

Eli Lilly & Co (LLY) Gets a Buy from RBC Capital

TIPRANKS
·
Oct 03

RBC Capital Sticks to Their Buy Rating for GE Healthcare Technologies Inc (GEHC)

TIPRANKS
·
Oct 03

The Oceania Healthcare Dispute Was About Profit, Not Growth

Simply Wall St.
·
Oct 03

Perrigo Co. PLC Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Oct 03

Molina Healthcare Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Oct 03

Aveanna Healthcare director resignation prompts governance reshuffle

TIPRANKS
·
Oct 03

AbbVie Joins US Government Pilot to Test Drug Discount Rebates

Reuters
·
Oct 03

Healthcare Stocks Fall Slightly

Dow Jones
·
Oct 03

S&P 500 Posts Slight Weekly Drop as Health Care, Financials Weigh

MT Newswires Live
·
Oct 03

AbbVie Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Oct 03

Abbvie-from Jan 1, 2027, Covered Entities to Submit Claims to GET 340B Pricing Through Beacon on 340B-Eligible Dispenses of Imbruvica, Linzess,Vraylar

THOMSON REUTERS
·
Oct 03

Abbvie - Approved to Participate in Federal 340B Rebate Model Pilot Program

THOMSON REUTERS
·
Oct 03

Former Eli Lilly Exec Sells Wyoming Estate for Close to $39.5 Million

Dow Jones
·
Oct 03

Why Medtronic's $4 Billion MiniMed Exchange Offer is Losing Its Allure

Dow Jones
·
Oct 03

Eli Lilly announces FDA approves additional indication for Jaypirca

TIPRANKS
·
Oct 03

Lilly Says FDA Approves Expanded First-Line Cll/sll Use for Jaypirca

Reuters
·
Oct 03

Lilly's Jaypirca (Pirtobrutinib), the First-and-Only Approved Non-Covalent Btk Inhibitor, Receives Expanded Indication from U.S. FDA for Certain Patients with Previously Untreated Cll/Sll

THOMSON REUTERS
·
Oct 03